This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hahner, S. Articles by Schirbel, A. Search for Related Content PubMed PubMed Citation Articles by Hahner, S. Articles by Schirbel, A. Related Collections Adrenal and Hypertension Endocrine Oncology

[¹²³I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes

Endocrinology and Diabetes Unit (S.H., A.St., M.F., M.Z., K.L., B.A.), Department of Medicine I, and Department of Nuclear Medicine (M.K., C.R., H.H., A.Sc.), University of Wuerzburg, D-97080 Wuerzburg, Germany; and Medical Clinic (F.B.), University Hospital Innenstadt, Ludwig Maximilians University, D-80336 Munich, Germany

Address all correspondence and requests for reprints to: Prof. Dr. Bruno Allolio, M.D., Endocrinology and Diabetes Unit, Department of Medicine, University of Wuerzburg, Josef-Schneider-Strasse 2, D-97080 Wuerzburg, Germany. E-mail: allolio_b{at}medizin.uni-wuerzburg.de.

Background: Due to advances in conventional imaging, adrenal tumors are detected with increasing frequency. However, conventional imaging provides only limited information on the origin of these lesions, which represent a wide range of different pathological entities. New specific imaging methods would therefore be of great clinical value. We, therefore, studied the potential of iodometomidate (IMTO) as tracer for molecular imaging of cytochrome P450 family 11B (Cyp11B) enzymes.

Methods: Inhibition of Cyp11B1 and Cyp11B2 by IMTO, etomidate, metomidate, and fluoroetomidate was investigated in NCI-h295 cells and in Y1 cells stably expressing hsCyp11B1 or hsCyp11B2. Pharmacokinetics and biodistribution after iv injection of [^123/125I]IMTO were analyzed in mice in biodistribution experiments and by small-animal single-photon emission computed tomography (SPECT). Furthermore, four patients with known adrenal tumors (two metastatic adrenal adenocarcinomas, one bilateral adrenocortical adenoma, and one melanoma metastasis) were investigated with [¹²³I]iodometomidate-SPECT.

Results: In cell culture experiments, all compounds potently inhibited both Cyp11B1 and Cyp11B2. Adrenals showed high and specific uptake of [^123/125I]IMTO and were excellently visualized in mice. In patients, adrenocortical tissue showed high and specific tracer uptake in both primary tumor and metastases with short investigation time and low radiation exposure, whereas the non-adrenocortical tumor did not exhibit any tracer uptake.

Conclusion: We have successfully completed the development of an in vivo detection system of adrenal Cyp11B enzymes by [¹²³I]IMTO scintigraphy in both experimental animals and humans. Our findings suggest that [¹²³I]IMTO is a highly specific radiotracer for imaging of adrenocortical tissue. Due to the general availability of SPECT technology, we anticipate that [¹²³I]IMTO scintigraphy may become a widely used tool to characterize adrenal lesions.